peginterferon beta-1a

Biogen’s Longer-Lasting MS Drug Meets Goals in Late Trial
Bloomberg
Thu, 01/24/13 - 10:33 am
MS
Biogen Idec
multiple sclerosis
peginterferon beta-1a